Alitretinoin in the treatment of cutaneous T‐cell lymphoma
Abstract Introduction In this survey, we analyzed data from patients suffering from the most common cutaneous T‐cell lymphomas (CTCLs) subtypes mycosis fungoides (MF) and Sézary syndrome (SS), treated with the retinoid alitretinoin during a 7‐year period at our outpatient department between 2015 and...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-10-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4237 |
| _version_ | 1831588683669569536 |
|---|---|
| author | Till Kaemmerer Pia‐Charlotte Stadler Leonie Helene Frommherz Anne Guertler Lars Einar French Markus Reinholz |
| author_facet | Till Kaemmerer Pia‐Charlotte Stadler Leonie Helene Frommherz Anne Guertler Lars Einar French Markus Reinholz |
| author_sort | Till Kaemmerer |
| collection | DOAJ |
| description | Abstract Introduction In this survey, we analyzed data from patients suffering from the most common cutaneous T‐cell lymphomas (CTCLs) subtypes mycosis fungoides (MF) and Sézary syndrome (SS), treated with the retinoid alitretinoin during a 7‐year period at our outpatient department between 2015 and 2020. Materials and Methods We analyzed patient medical records including TNMB stage, side effects under therapy with alitretinoin, time to next treatment (TTNT), and previous photo documentation. Results A total of 35 patients with MF (n = 28) and SS (n = 7) were included in the study, of whom 69% were male and 31% were female. The mean age of onset was 56 ± 15 years in MF and 65.4 ± 10.8 years in SS with 51.4% having early stage (IA–IIA) and 48.6% having advanced stage (IIB–IVA) CTCL. Of these patients 37.2% responded to alitretinoin, 28.6% had a stable course, and 34.3% experienced progression. Alitretinoin was administered as a monotherapy (25.7%) or combined with five concomitant therapies (74.2%), most frequently with ECP (31.4%) and PUVA (11.4%). 63% did not report any side effects, most often hypertriglyceridemia (20%) was described. Conclusion Considering that nearly two thirds of the CTCL patients treated with alitretinoin showed a response or stable disease, together with a low number of side effects and low cost compared to bexarotene, alitretinoin may be a potential alternative in the treatment of less advanced CTCLs. This survey represents the largest number of recorded therapies with the retinoid alitretinoin in CTCLs in a European patient collective. |
| first_indexed | 2024-12-17T22:17:38Z |
| format | Article |
| id | doaj.art-1b3580a806c944e2a0e184b546df5927 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-12-17T22:17:38Z |
| publishDate | 2021-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-1b3580a806c944e2a0e184b546df59272022-12-21T21:30:33ZengWileyCancer Medicine2045-76342021-10-0110207071707810.1002/cam4.4237Alitretinoin in the treatment of cutaneous T‐cell lymphomaTill Kaemmerer0Pia‐Charlotte Stadler1Leonie Helene Frommherz2Anne Guertler3Lars Einar French4Markus Reinholz5Department of Dermatology and Allergy University HospitalLMU Munich GermanyDepartment of Dermatology and Allergy University HospitalLMU Munich GermanyDepartment of Dermatology and Allergy University HospitalLMU Munich GermanyDepartment of Dermatology and Allergy University HospitalLMU Munich GermanyDepartment of Dermatology and Allergy University HospitalLMU Munich GermanyDepartment of Dermatology and Allergy University HospitalLMU Munich GermanyAbstract Introduction In this survey, we analyzed data from patients suffering from the most common cutaneous T‐cell lymphomas (CTCLs) subtypes mycosis fungoides (MF) and Sézary syndrome (SS), treated with the retinoid alitretinoin during a 7‐year period at our outpatient department between 2015 and 2020. Materials and Methods We analyzed patient medical records including TNMB stage, side effects under therapy with alitretinoin, time to next treatment (TTNT), and previous photo documentation. Results A total of 35 patients with MF (n = 28) and SS (n = 7) were included in the study, of whom 69% were male and 31% were female. The mean age of onset was 56 ± 15 years in MF and 65.4 ± 10.8 years in SS with 51.4% having early stage (IA–IIA) and 48.6% having advanced stage (IIB–IVA) CTCL. Of these patients 37.2% responded to alitretinoin, 28.6% had a stable course, and 34.3% experienced progression. Alitretinoin was administered as a monotherapy (25.7%) or combined with five concomitant therapies (74.2%), most frequently with ECP (31.4%) and PUVA (11.4%). 63% did not report any side effects, most often hypertriglyceridemia (20%) was described. Conclusion Considering that nearly two thirds of the CTCL patients treated with alitretinoin showed a response or stable disease, together with a low number of side effects and low cost compared to bexarotene, alitretinoin may be a potential alternative in the treatment of less advanced CTCLs. This survey represents the largest number of recorded therapies with the retinoid alitretinoin in CTCLs in a European patient collective.https://doi.org/10.1002/cam4.4237cancer managementdrug discovery and deliverynon‐Hodgkin's lymphomasurvival |
| spellingShingle | Till Kaemmerer Pia‐Charlotte Stadler Leonie Helene Frommherz Anne Guertler Lars Einar French Markus Reinholz Alitretinoin in the treatment of cutaneous T‐cell lymphoma Cancer Medicine cancer management drug discovery and delivery non‐Hodgkin's lymphoma survival |
| title | Alitretinoin in the treatment of cutaneous T‐cell lymphoma |
| title_full | Alitretinoin in the treatment of cutaneous T‐cell lymphoma |
| title_fullStr | Alitretinoin in the treatment of cutaneous T‐cell lymphoma |
| title_full_unstemmed | Alitretinoin in the treatment of cutaneous T‐cell lymphoma |
| title_short | Alitretinoin in the treatment of cutaneous T‐cell lymphoma |
| title_sort | alitretinoin in the treatment of cutaneous t cell lymphoma |
| topic | cancer management drug discovery and delivery non‐Hodgkin's lymphoma survival |
| url | https://doi.org/10.1002/cam4.4237 |
| work_keys_str_mv | AT tillkaemmerer alitretinoininthetreatmentofcutaneoustcelllymphoma AT piacharlottestadler alitretinoininthetreatmentofcutaneoustcelllymphoma AT leoniehelenefrommherz alitretinoininthetreatmentofcutaneoustcelllymphoma AT anneguertler alitretinoininthetreatmentofcutaneoustcelllymphoma AT larseinarfrench alitretinoininthetreatmentofcutaneoustcelllymphoma AT markusreinholz alitretinoininthetreatmentofcutaneoustcelllymphoma |